Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 430Neoplasms 284Carcinoma, Non-Small-Cell Lung 266Colorectal Neoplasms 228Lung Neoplasms 173Prostatic Neoplasms 171Carcinoma, Hepatocellular 156Stomach Neoplasms 129Leukemia, Myeloid, Acute 118Pancreatic Neoplasms 115Multiple Myeloma 105Recurrence 96Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 88Neoplasm Metastasis 87Rectal Neoplasms 85Ovarian Neoplasms 77Triple Negative Breast Neoplasms 75Small Cell Lung Carcinoma 72Head and Neck Neoplasms 68Brain Neoplasms 68Esophageal Neoplasms 64Glioblastoma 63Colonic Neoplasms 60Endometrial Neoplasms 58Melanoma 54Hematologic Neoplasms 53Motor Activity 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Nasopharyngeal Carcinoma 46

Interventions

pembrolizumab 2lenvatinib 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Advanced Endometrial Cancer × Clear all
NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡